Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: hotlinktuna who wrote (54618)	4/12/2006 10:30:46 AM
From: Blue h2o	Read Replies (1) \| Respond to of 59879

BOCX...News BioCurex Blood Test Detects Very Early Stages of Breast Cancer With High Specificity Business Wire - April 12, 2006 09:30 RICHMOND, British Columbia, Apr 12, 2006 (BUSINESS WIRE) -- BioCurex Inc. (Pink Sheets:BOCX) announced today that its RECAF blood test for cancer is able to detect very early stages of breast cancer with a high degree of accuracy. The study was blinded in that the actual diagnosis was not disclosed to BioCurex until after the test was performed. All samples were verified as early stage cancers -- Stage I and Stage II. (There are four stages of cancer identifying the progression of the disease). he table below shows the Sensitivity values with a specificity of 100% against normal patient samples (100% specificity means no false positives). Cancer Stage(a) SENSITIVITY SPECIFICITY SAMPLES --------------- ----------- ----------- ------- Stage I 90% 100% 42 Stage II 93% 100% 45 Dr. Moro, President, stated: "We are very pleased with the data presented, which are consistent with previous results obtained on tissue sections. The results unequivocally illustrate the potential RECAF has to offer for early cancer detection and we anticipate that the results for other cancer types will be consistent with these findings reported for breast cancer. This level of accuracy is particularly significant for a screening test since early detection is the key when it comes to fighting cancer. "Previous reports have demonstrated the ability of RECAF to detect many types of cancer from tissue biopsy specimens and blood tests due to the presence of RECAF receptor on the surface of malignant cells, but not normal cells. However, using blood samples of verified early stage cancers, we can now further delineate the value of RECAF for the world population in a humanistic and economic fashion." The following statistics illustrate the importance of early diagnosis in relation to the outcome of breast cancer: Patients diagnosed at Stage I have a 5 year survival of 87%. At Stage II the 5 year survival rate is still high (75%). Survival drops to 46% when the patient is diagnosed at Stage III and at Stage IV it is only 13%(b). It is well known that the costs to treat an early stage cancer are significantly less and the survival rate is much higher when a cancer is detected early. The current standard for breast cancer screening is mammography. In the USA, the sensitivity of mammography to detect cancer is approximately 65-75% with 90% specificity (i.e. with 10% of false positives)(c). Medicare pays $135 for a digital mammogram and $85 for film(d). About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(TM) Cancer technology. Studies from the investigators at BioCurex and elsewhere have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. To read more about the Company, please visit the News section in our web site (www.biocurex.com).